Peptide Storage: Lyophilized vs Reconstituted Stability

"How long does it last in the fridge?" is one of the most common questions we get. For most research peptides, the honest answer is that nobody has published the data.

Drug developers study degradation in detail, partly to set shelf life (Pace 2013). Many research peptides have not been through that process. Take BPC-157, one of the most discussed compounds in our library: a 2026 review of its pharmaceutical development concluded that no pharmaceutical-grade formulation has been developed or validated, and that the peptide lacks formal excipient compatibility studies (Mateescu 2026). The same review notes BPC-157's unusual stability in gastric juice, which is a different question from how long a reconstituted vial keeps.

What does exist is a large pharmaceutical literature on how peptides and proteins degrade in general. It cannot give you a shelf life for a specific vial. It can tell you which variables matter and why. This article sticks to what that literature supports, and it does not give shelf-life numbers, because for these compounds there are none we can source.

Two kinds of breakdown

Researchers split peptide and protein instability into two broad families (Manning 2010):

• Chemical instability: covalent bonds change, producing a different molecule.
• Physical instability: the molecule's shape or association changes, for example by unfolding or clumping together, without the bonds necessarily changing.

The same review discusses how the two are interrelated, so one kind of change can feed into the other.

Chemical pathways

Hydrolysis (peptide bond cleavage). Water can break the backbone of a peptide, splitting it into fragments. In a study of recombinant human parathyroid hormone, a peptide hormone, the main degradation route under acidic conditions was cleavage of the backbone at aspartic acid residues (Nabuchi 1997).

Deamidation. The amino acid asparagine can lose its amide group and convert to aspartate or isoaspartate. It is described as a major chemical degradation pathway for antibody drugs, and one that can affect shelf life (Pace 2013). In the parathyroid hormone study, deamidation of asparagine became the more prominent pathway as pH rose above 5, and the hormone was most stable at pH 5 (Nabuchi 1997). In other words, the conditions that slow one reaction can speed up another.

Oxidation. Several amino acids are prone to oxidation during storage, including methionine, cysteine, histidine, tyrosine, tryptophan, and phenylalanine (Grassi 2019). The same review covers cyclization and elimination reactions, further routes by which a stored protein can change.

Physical pathways

Aggregation. Peptide or protein molecules can stick together into clumps, some soluble and some visible as particles. Aggregation is a form of physical instability, and it is relevant to reconstitution: in one experiment, reconstituting a freeze-dried therapeutic protein with water containing 0.9% benzyl alcohol, the preservative in bacteriostatic water, caused more aggregation than reconstituting it with plain water (Roy 2005). In the same study, benzyl alcohol did not speed up aggregation during later room-temperature storage of the reconstituted samples. That was one protein, not a research peptide, but it shows the liquid is not a neutral choice.

Why freeze-dried is more stable

Research peptides are commonly sold lyophilized: freeze-dried into a powder. The pharmaceutical reason is straightforward. Proteins have limited stability in solution, so they often have to be made into solid forms to achieve an acceptable shelf life, and freeze-drying is the most common way to do it (Wang 2000).

How large can the difference be? In a study of two model peptides at 50 °C, deamidation ran 2- to 80-fold more slowly in freeze-dried solids made with sucrose or mannitol than in 5% solutions of the same sugars (Li 2005). Those were short model peptides under accelerated laboratory conditions, so the figure is an illustration of the principle, not a prediction for any product.

Dry is not the same as invulnerable:

• Freeze-drying itself is a stress. Freezing and drying can damage proteins to varying degrees, and even a successfully dried product may have limited long-term stability (Wang 2000).
• Moisture undoes the benefit. In a freeze-dried enzyme, aggregation and loss of activity increased as relative humidity increased (Flores-Fernández 2010). A dry cake that picks up water is on its way back to being a solution.

The practical point is the one that matters most for readers: once a vial is reconstituted, the peptide is in its less stable form. Reviewers of peptide formulation note that peptides are often unstable in aqueous solution, and that pH optimization and buffer choice are the most practical ways formulators slow that down (Nugrahadi 2023). Whether the contents of a given research vial were formulated with that in mind, you usually cannot tell.

Temperature

Chemical reactions generally run faster when warmer, and peptide degradation is no exception. In a model peptide, deamidation followed a predictable temperature relationship (Arrhenius behaviour) across 5 to 65 °C (Stratton 2001).

Temperature interacts with everything else. In one antibody study, deamidation was faster in acidic buffers than basic ones at 40 °C, but the trend reversed at 5 °C (Pace 2013). That is a caution against assuming that results from warm, accelerated tests translate neatly to refrigerated storage.

For one compound that does have published work, a stress study of semaglutide in solution at 25 °C to 80 °C identified thirteen degradation impurities and found pH was a key factor in its thermal degradation (Malgave 2025). That is a preformulation study, not a shelf-life study, and it does not tell you how long any particular semaglutide solution lasts.

Freezing and thawing

Freezing sounds like the safe option, but the literature is mixed. Very low temperatures and the thick, concentrated liquid that forms between ice crystals can stabilize proteins. Freezing also changes temperature, pH, and salt concentration, and proteins can adsorb to the ice surface, unfold, and aggregate (Li 2025). The same review describes freeze and thaw rates as something formulators have to control carefully. In short, freeze-thaw is a recognized stress, not a free pass.

Light

Light is another degradation route. The amino acids most prone to light-driven oxidation include tryptophan, tyrosine, phenylalanine, and cysteine, and light damage can change a protein's structure (Kerwin 2007). The authors also note that data on the photodegradation of biopharmaceutical products specifically is limited, which is a theme of this whole topic.

What this adds up to

The literature does not hand you a number. It gives you a list of variables that consistently matter: water, temperature, pH, oxygen, light, freeze-thaw cycles, and the other things in the vial, including the preservative. Each is supported by pharmaceutical research on peptides and proteins in general. None has been measured for most research peptides specifically.

Two more points follow from that:

• Degradation is invisible. Hydrolysis, deamidation, and oxidation produce molecules that look identical in a vial. Detecting them takes laboratory methods such as HPLC and mass spectrometry, which is how the semaglutide study above identified its impurities. A certificate of analysis describes a sample at the time it was tested, not after months in your fridge.
• Treat specific shelf-life claims with care. If someone gives a precise number of days for a reconstituted research peptide, it is worth asking where it came from. For most of these compounds, we could not find a published source.

For the arithmetic of reconstitution itself, see the peptide calculator. For how we verify the studies cited across the site, see our methodology.

Sources

• BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 2026. PMID 42198317
• Stability of protein pharmaceuticals: an update. Pharm Res, 2010. PMID 20143256
• The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues. Pharm Res, 1997. PMID 9453054
• Asparagine deamidation dependence on buffer type, pH, and temperature. J Pharm Sci, 2013. PMID 23568760
• Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions. Amino Acids, 2019. PMID 31576455
• Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci, 2005. PMID 15614819
• Lyophilization and development of solid protein pharmaceuticals. Int J Pharm, 2000. PMID 10967427
• Effects of sucrose and mannitol on asparagine deamidation rates of model peptides in solution and in the solid state. J Pharm Sci, 2005. PMID 15986465
• Moisture-induced solid state instabilities in alpha-chymotrypsin and their reduction through chemical glycosylation. BMC Biotechnol, 2010. PMID 20696067
• Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics, 2023. PMID 36986796
• Controlling deamidation rates in a model peptide: effects of temperature, peptide concentration, and additives. J Pharm Sci, 2001. PMID 11745773
• Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery. Eur J Pharm Biopharm, 2025. PMID 40490042
• Protein stability and critical stabilizers in frozen solutions. Eur J Pharm Biopharm, 2025. PMID 40490041
• Protect from light: photodegradation and protein biologics. J Pharm Sci, 2007. PMID 17230445

This article is for educational and research purposes only and is not medical advice.